ERCP术后胆总管结石复发预测模型的构建与验证

陈文杰, 徐岚, 许春芳. ERCP术后胆总管结石复发预测模型的构建与验证[J]. 中国中西医结合消化杂志, 2022, 30(6): 383-388. doi: 10.3969/j.issn.1671-038X.2022.06.01
引用本文: 陈文杰, 徐岚, 许春芳. ERCP术后胆总管结石复发预测模型的构建与验证[J]. 中国中西医结合消化杂志, 2022, 30(6): 383-388. doi: 10.3969/j.issn.1671-038X.2022.06.01
CHEN Wenjie, XU Lan, XU Chunfang. Construction and validation of a novel nomogram for predicting recurrent choledocholithiasis after ERCP[J]. Chin J Integr Tradit West Med Dig, 2022, 30(6): 383-388. doi: 10.3969/j.issn.1671-038X.2022.06.01
Citation: CHEN Wenjie, XU Lan, XU Chunfang. Construction and validation of a novel nomogram for predicting recurrent choledocholithiasis after ERCP[J]. Chin J Integr Tradit West Med Dig, 2022, 30(6): 383-388. doi: 10.3969/j.issn.1671-038X.2022.06.01

ERCP术后胆总管结石复发预测模型的构建与验证

详细信息
    通讯作者: 许春芳,E-mail:xcf601@163.com
  • 中图分类号: R575.6

Construction and validation of a novel nomogram for predicting recurrent choledocholithiasis after ERCP

More Information
  • 目的 探讨经内镜逆行胰胆管造影(ERCP)取石术后胆总管结石(CBDS)复发的危险因素,绘制列线图风险预测模型,并进行验证。方法 选取2017年1月—2020年12月期间于苏州大学附属第一医院消化内科行ERCP治疗的胆总管结石患者共计665例,按照8∶2随机抽取,532例(80%)作为建模组,133例(20%)作为验证组,根据结石是否复发,分为复发组和未复发组,比较2组患者资料差异,运用单因素和多因素分析筛选出ERCP术后胆总管结石复发的独立危险因素,绘制列线图风险预测模型,并进行验证。结果 在建模组532例患者中,131例复发,复发率24.6%。多因素logistic回归分析显示胆囊切除术后、胆总管扩张、胆汁细菌培养阳性、乳头括约肌切开是ERCP术后胆总管结石复发的独立危险因素(P< 0.05)。在建模组和验证组中,列线图模型的C指数和AUC值分别为0.810(95%CI:0.770~0.846)、0.851(95%CI:0.771~0.912),校正C指数分别为0.822、0.862,校正曲线表明预测结果和实际结果之间具有良好的一致性。决策曲线表示该模型有较高的临床应用价值。结论 胆囊切除术后、胆总管扩张、胆汁细菌培养阳性、十二指肠乳头括约肌切开是ERCP术后胆总管结石复发的独立危险因素。本研究构建了一个新型ERCP术后胆总管结石复发的风险预测模型,经验证具有良好的区分度、一致性和临床实用性。
  • 加载中
  • 图 1  ERCP术后胆总管结石复发风险预测列线图

    图 2  建模组和验证组中列线图的ROC曲线

    图 3  建模组和验证组中列线图模型的校准图

    图 4  经Bootstrap法验证后建模组和验证组的校准曲线

    图 5  列线图模型的临床决策曲线和临床影响曲线

    表 1  建模组中未复发与复发患者单因素分析

    变量 未复发(n=401) 复发(n=131) P
    女性/例(%) 172(42.9) 58(44.3) 0.782
    年龄>65岁/例(%) 202(50.4) 67(51.1) 0.878
    体重指数/(kg/m2) 23.5±3.2 22.6±3.2 0.013
    aCCI 3.0(1.0,4.0) 3.0(1.0,4.0) 0.888
    WBC/(×109·L-1) 4.6(3.7,7.9) 5.6(4.4,7.8) 0.653
    NE/(×109·L-1) 3.6(2.6,5.7) 3.4(2.6,5.5) 0.872
    PCT/(ng·mL-1) 0.1(0.0,0.6) 0.1(0.0,0.6) 0.297
    TBIL/(μmol·L-1) 22.4(15.2,58.4) 18.6(12.3,32.1) 0.001
    ALT/(U·L-1) 74.4(24.7,190.2) 35.0(17.4,120.1) 0.001
    AST/(U·L-1) 40.6(21.6,105.3) 27.4(19.4,65.7) 0.002
    GGT/(U·L-1) 251.1(83.8,501.6) 172.5(47.1,335.5) 0.001
    ALP/(U·L-1) 136.7(91.9,414.7) 111.7(80.9,201.8) 0.007
    术后胰腺炎/例(%) 18(4.5) 5(3.8) 0.735
    高淀粉酶血症/例(%) 124(30.9) 30(22.9) 0.074
    既往胆道手术史/例(%) 37(9.2) 25(19.1) 0.002
    胆囊状态/例(%) < 0.001
      a 80(20.0) 18(13.7)
      b 135(33.7) 10(7.6)
      c 129(32.2) 96(73.3)
      d 57(14.2) 7(5.3)
    术前胆管炎/例(%) 152(37.9) 52(39.7) 0.715
    结石数目多发/例(%) 228(56.9) 84(64.1) 0.143
    结石直径/mm 8.0(8.0,11.0) 10.0(8.0,15.0) < 0.001
    结石位于中下段/例(%) 279(69.6) 92(69.2) 0.385
    胆总管直径/mm 12.0(10.0,18.0) 15.0(12.0,18.0) < 0.001
    胆汁培养阳性/例(%) 176(52.4) 22(21.6) < 0.001
    壶腹周围憩室/例(%) 104(25.9) 31(31.0) 0.604
    乳头括约肌切开/例(%) 339(84.5) 51(46.8) < 0.001
    乳头切开长度/mm 5.0(3.0,5.0) 5.0(3.0,5.0) 0.034
    治疗方式/例(%) < 0.001
      EST 58(14.6) 13(19.4)
      EPBD 57(14.4) 16(23.9)
      sEST-EPBD 281(71.0) 38(56.7)
    胆道支架置入/例(%) 88(22.1) 25(19.1) 0.463
    鼻胆管引流/例(%) 322(80.5) 98(74.2) 0.126
    注:EST,内镜下乳头括约肌切开术;EPBD,内镜下乳头括约肌球囊扩张术;sEST-EPBD,内镜下乳头括约肌小切开术联合乳头球囊扩张术。
    下载: 导出CSV

    表 2  多因素logistic回归分析

    变量 OR 95%CI P
    胆囊术后 4.581 2.807~7.477 <0.001
    胆总管直径 1.088 1.037~1.141 0.001
    乳头括约肌切开 2.833 1.429~3.802 0.001
    胆汁细菌培养阳性 2.611 1.513~4.525 0.001
    下载: 导出CSV
  • [1]

    Cai JS, Qiang S, Bao-Bing Y. Advances of recurrent risk factors and management of choledocholithiasis[J]. Scand J Gastroenterol, 2017, 52(1): 34-43. doi: 10.1080/00365521.2016.1224382

    [2]

    ASGE Standards of Practice Committee, Buxbaum JL, Abbas Fehmi SM, et al. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis[J]. Gastrointest Endosc, 2019, 89(6): 1075-1105.e15. doi: 10.1016/j.gie.2018.10.001

    [3]

    Wu Y, Xu CJ, Xu SF. Advances in Risk Factors for Recurrence of Common Bile Duct Stones[J]. Int J Med Sci, 2021, 18(4): 1067-1074. doi: 10.7150/ijms.52974

    [4]

    Oak JH, Paik CN, Chung WC, et al. Risk factors for recurrence of symptomatic common bile duct stones after cholecystectomy[J]. Gastroenterol Res Pract, 2012, 2012: 417821.

    [5]

    Li S, Su B, Chen P, et al. Risk factors for recurrence of common bile duct stones after endoscopic biliary sphincterotomy[J]. J Int Med Res, 2018, 46(7): 2595-2605. doi: 10.1177/0300060518765605

    [6]

    Park SY, Hong TH, Lee SK, et al. Recurrence of common bile duct stones following laparoscopic common bile duct exploration: a multicenter study[J]. J Hepatobiliary Pancreat Sci, 2019, 26(12): 578-582. doi: 10.1002/jhbp.675

    [7]

    Yoo ES, Yoo BM, Kim JH, et al. Evaluation of risk factors for recurrent primary common bile duct stone in patients with cholecystectomy[J]. Scand J Gastroenterol, 2018, 53(4): 466-470. doi: 10.1080/00365521.2018.1438507

    [8]

    Park BK, Seo JH, Jeon HH, et al. A nationwide population-based study of common bile duct stone recurrence after endoscopic stone removal in Korea[J]. J Gastroenterol, 2018, 53(5): 670-678. doi: 10.1007/s00535-017-1419-x

    [9]

    Zhang R, Luo H, Pan Y, et al. Rate of duodenal-biliary reflux increases in patients with recurrent common bile duct stones: evidence from barium meal examination[J]. Gastrointest Endosc, 2015, 82(4): 660-665. doi: 10.1016/j.gie.2015.03.1908

    [10]

    Konstantakis C, Triantos C, Theopistos V, et al. Recurrence of choledocholithiasis following endoscopic bile duct clearance: Long term results and factors associated with recurrent bile duct stones[J]. World J Gastrointest Endosc, 2017, 9(1): 26-33. doi: 10.4253/wjge.v9.i1.26

    [11]

    Paspatis GA, Paraskeva K, Vardas E, et al. Long-term recurrence of bile duct stones after endoscopic papillary large balloon dilation with sphincterotomy: 4-year extended follow-up of a randomized trial[J]. Surg Endosc, 2017, 31(2): 650-655. doi: 10.1007/s00464-016-5012-9

    [12]

    黄瑶, 易剑锋, 周文策. 胆总管结石治疗后复发因素的研究进展[J]. 中国普通外科杂志, 2021, 30(8): 964-970. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202108012.htm

    [13]

    王士东. ERCP取石术后胆总管结石复发的相关因素分析[D]. 青岛: 青岛大学, 2020.

    [14]

    Keizman D, Shalom MI, Konikoff FM. An angulated common bile duct predisposes to recurrent symptomatic bile duct stones after endoscopic stone extraction[J]. Surg Endosc, 2006, 20(10): 1594-1599. doi: 10.1007/s00464-005-0656-x

    [15]

    Nzenza TC, Al-Habbal Y, Guerra GR, et al. Recurrent common bile duct stones as a late complication of endoscopic sphincterotomy[J]. BMC Gastroenterol, 2018, 18(1): 39. doi: 10.1186/s12876-018-0765-3

    [16]

    Gulubov MV, Hadjipetkov P, Sivrev D, et al. Endocrine cells in the human common bile duct in patients with obstructive jaundice[J]. Hepatogastroenterology, 2012, 59(113): 26-30.

    [17]

    Jeon J, Lim SU, Park CH, et al. Restoration of common bile duct diameter within 2 weeks after endoscopic stone retraction is a preventive factor for stone recurrence[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(3): 251-256. doi: 10.1016/j.hbpd.2018.03.014

    [18]

    Deng F, Zhou M, Liu PP, et al. Causes associated with recurrent choledocholithiasis following therapeutic endoscopic retrograde cholangiopancreatography: A large sample sized retrospective study[J]. World J Clin Cases, 2019, 7(9): 1028-1037. doi: 10.12998/wjcc.v7.i9.1028

    [19]

    郝志远. 胆总管结石合并胆管炎肠道微生态宏基因组测序及代谢组学分析[D]. 上海: 中国人民解放军海军军医大学, 2021.

    [20]

    王志毅. 胆总管结石合并胆囊结石经ERCP联合LC后胆总管结石复发的危险因素分析[D]. 苏州: 苏州大学, 2020.

    [21]

    Wu SD, Uchiyama K, Fan Y. The role and mechanism of fatty acids in gallstones[J]. Hepatobiliary Pancreat Dis Int, 2007, 6(4): 399-401.

    [22]

    李静, 苗龙, 周文策. 消化道微生态与胆结石疾病关系的研究进展[J]. 中国普通外科杂志, 2020, 29(8): 1000-1005. https://www.cnki.com.cn/Article/CJFDTOTAL-ZPWZ202008016.htm

    [23]

    Tsai TJ, Lin CK, Lai KH, et al. Does preserved sphincter of Oddi function prevent common bile duct stones recurrence in patients after endoscopic papillary balloon dilation?[J]. J Chin Med Assoc, 2018, 81(4): 311-315. doi: 10.1016/j.jcma.2018.01.007

    [24]

    Minakari M, Samani RR, Shavakhi A, et al. Endoscopic papillary balloon dilatation in comparison with endoscopic sphincterotomy for the treatment of large common bile duct stone[J]. Adv Biomed Res, 2013, 2: 46. doi: 10.4103/2277-9175.114186

    [25]

    Ryozawa S, Itoi T, Katanuma A, et al. Japan Gastroenterological Endoscopy Society guidelines for endoscopic sphincterotomy[J]. Dig Endosc, 2018, 30(2): 149-173. doi: 10.1111/den.13001

    [26]

    Yamamoto R, Tazuma S, Kanno K, et al. Ursodeoxycholic acid after bile duct stone removal and risk factors for recurrence: a randomized trial[J]. J Hepatobiliary Pancreat Sci, 2016, 23(2): 132-136. doi: 10.1002/jhbp.316

    [27]

    李志晋, 徐燕琴, 洪丽华, 等. 鼻胆管灌注柴胡四金汤对预防胆总管结石ERCP术后复发的效果观察[J]. 江西医药, 2021, 56(9): 1540-1542. doi: 10.3969/j.issn.1006-2238.2021.09.072

    [28]

    Fukuba N, Ishihara S, Sonoyama H, et al. Proton pump inhibitor is a risk factor for recurrence of common bile duct stones after endoscopic sphincterotomy-propensity score matching analysis[J]. Endosc Int Open, 2017, 5(4): E291-E296. doi: 10.1055/s-0043-102936

    [29]

    Uchida N, Hamaya S, Tatsuta M, et al. Extracorporeal abdominal massage may help prevent recurrent bile duct stones after endoscopic sphincterotomy[J]. Endosc Int Open, 2016, 4(8): E870-E873. doi: 10.1055/s-0042-109774

    [30]

    Di Ciaula A, Garruti G, Frühbeck G, et al. The Role of Diet in the Pathogenesis of Cholesterol Gallstones[J]. Curr Med Chem, 2019, 26(19): 3620-3638. doi: 10.2174/0929867324666170530080636

  • 加载中

(5)

(2)

计量
  • 文章访问数:  806
  • PDF下载数:  744
  • 施引文献:  0
出版历程
收稿日期:  2022-04-01
刊出日期:  2022-06-15

目录